Marker Therapeutics
MRKR
8 hedge funds and large institutions have $302K invested in Marker Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
303% more capital invested
Capital invested by funds: $75K → $302K (+$227K)
60% more funds holding
Funds holding: 5 → 8 (+3)
0.08% more ownership
Funds ownership: 0.02% → 0.1% (+0.08%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$258K |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$316 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$221 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$158 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $246K | +$258K | +8,185 | New |
|
|
2
BlackRock
New York
| $42K | -$2.52K | -80 | -5% |
|
|
NSIM
3
North Star Investment Management
Chicago,
Illinois
| $7K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $6K | +$158 | +5 | +2% |
|
|
AG
5
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| – | +$221 | +7 | New |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$316 | +10 | New |
|
MRKR Hedge Fund Activity: Q3 2017 in Review
8 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2017, worth a combined $302K — up 303% from $75K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MRKR positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $258K. The largest seller was BlackRock, cutting an estimated $2.52K.
- 8 institutional investors held Marker Therapeutics (MRKR) as of Q3 2017, up from 5 in Q2 2017.
- Funds reported $302K of Marker Therapeutics stock for Q3 2017, up 303% quarter-over-quarter.
- 3 funds opened new Marker Therapeutics positions in Q3 2017 and 0 closed out, a net change of +3 holders.
- The largest Marker Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $258K added.
- The largest Marker Therapeutics seller in Q3 2017 was BlackRock, an estimated $2.52K sold.
Based on aggregated 13F filings for Q3 2017.